NCT05621499 2022-11-18
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
Tianjin Medical University Cancer Institute and Hospital
Hunan Province Tumor Hospital
RenJi Hospital
The Central Hospital of Lishui City
Beijing Tiantan Hospital
Henan Provincial People's Hospital